遗传性额颞叶痴呆在GENFI队列中的纵向认知变化
本研究在GENFI前瞻性多中心队列中,对207例C9orf72、206例GRN、86例MAPT致病性变异携带者及255名对照每年进行涵盖8个认知域的神经心理评估,按CDR加NACC FTLD评分分层。结果证实遗传性额颞叶痴呆在无症状和前驱期已存在认知下降,不同基因群体和疾病阶段的认知变化速度不同。
要点
- C9orf72携带者从CDR加NACC FTLD 0分起注意力、执行功能和言语流畅性较低,随时间下降相对轻微。
- MAPT携带者在0.5分时记忆表现较低,语言自0.5分起下降,执行功能障碍在≥1分时快速出现。
- GRN携带者在0.5分时言语流畅性和视空间结构下降,其他认知域从≥1分起进行性下降。
核心结论
- 研究证实遗传性额颞叶痴呆在无症状和前驱期已存在认知下降,不同基因群体和疾病阶段的认知变化速度不同。
研究设计与样本
- 遗传性额颞叶痴呆倡议(GENFI)前瞻性多中心队列研究,纳入207例C9orf72、206例GRN、86例MAPT致病性变异携带者及255名对照,每年进行涵盖8个认知域的神经心理评估,携带者按CDR加NACC FTLD评分(0、0.5或≥1)分层,采用线性混合效应模型分析。
主要发现
- C9orf72携带者从CDR加NACC FTLD 0分起注意力、执行功能和言语流畅性表现较低,无论CDR加NACC FTLD评分如何,随时间下降相对轻微。
- MAPT携带者认知特征为CDR加NACC FTLD 0.5分时记忆表现较低,语言自0.5分起随时间下降,执行功能障碍在≥1分时快速出现。
- GRN携带者在CDR加NACC FTLD 0.5分时言语流畅性和视空间结构下降,其他认知域从≥1分起进行性下降。
- 基线时注意力、执行功能、语言和记忆测试显示基因群体与对照之间存在明显差异,但随时间变化的速度取决于基因群体和疾病阶段。
临床怎么用
- 作者认为神经心理评估在追踪临床起病和进展方面具有价值,可帮助临床试验选择测量治疗效果的敏感终点,并确定开始治疗的最佳时间窗口。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Disease-modifying therapeutic trials for genetic frontotemporal dementia (FTD) are underway, but sensitive cognitive outcome measures are lacking. The aim of this study was to identify such cognitive tests in early stage FTD by investigating cognitive decline in a large cohort of genetic FTD pathogenic variant carriers and by investigating whether gene-specific differences are moderated by disease stage (asymptomatic, prodromal, and symptomatic). METHODS: C9orf72, GRN, and MAPT pathogenic variant carriers as well as controls underwent a yearly neuropsychological assessment covering 8 cognitive domains as part of the Genetic FTD Initiative, a prospective multicenter cohort study. Pathogenic variant carriers were stratified according to disease stage using the global Clinical Dementia Rating (CDR) plus National Alzheimer's Coordinating Center (NACC) FTLD score (0, 0.5, or ≥1). Linear mixed-effects models were used to investigate differences between genetic groups and disease stages as well as the 3-way interaction between time, genetic group, and disease stage. RESULTS: A total of 207 C9orf72, 206 GRN, and 86 MAPT pathogenic variant carriers and 255 controls were included. C9orf72 pathogenic variant carriers performed lower on attention, executive function, and verbal fluency from CDR plus NACC FTLD 0 onwards, with relatively minimal decline over time regardless of the CDR plus NACC FTLD score (i.e., disease progression). The cognitive profile in MAPT pathogenic variant carriers was characterized by lower memory performance at CDR plus NACC FTLD 0.5, with decline over time in language from the CDR plus NACC FTLD 0.5 stage onwards, and executive dysfunction rapidly developing at CDR plus NACC FTLD ≥1. GRN pathogenic variant carriers declined on verbal fluency and visuoconstruction in the CDR plus NACC FTLD 0.5 stage, with progressive decline in other cognitive domains starting at CDR plus NACC FTLD ≥1. DISCUSSION: We confirmed cognitive decline in the asymptomatic and prodromal stage of genetic FTD. Specifically, tests for attention, executive function, language, and memory showed clear differences between genetic groups and controls at baseline, but the speed of change over time differed depending on genetic group and disease stage. This confirms the value of neuropsychological assessment in tracking clinical onset and progression and could inform clinical trials in selecting sensitive end points for measuring treatment effects as well as characterizing the best time window for starting treatment.
引用
- Poos JM, MacDougall A, van den Berg E, et al. Longitudinal Cognitive Changes in Genetic Frontotemporal Dementia Within the GENFI Cohort. Neurology. 2022. PMID: 35483895. doi:10.1212/WNL.0000000000200384
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。